Form 4: Dexcom EVP Jon Coleman Granted Over 68,000 Restricted Stock Units

Dexcom Inc.'s Executive Vice President and Chief Commercial Officer, Jon Coleman, has been granted 68,738 shares of common stock in the form of restricted stock units, aligning executive interests with shareholder value.

Summary

• Jon Coleman, Executive Vice President and Chief Commercial Officer of Dexcom Inc. (DXCM), acquired 68,738 shares of common stock.
• The acquisition was a grant of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs are subject to vesting in four equal annual installments from the grant date of May 22, 2025.
• Following this transaction, Jon Coleman beneficially owns 68,738 shares of Dexcom common stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a key executive is generally viewed positively as it aligns management's interests with shareholders and incentivizes long-term performance, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of restricted stock units to a key executive like the EVP, Chief Commercial Officer, aligns management's long-term interests with those of shareholders.
• Such equity grants are a common component of executive compensation, designed to incentivize performance and retention.

Future Outlook

The restricted stock units are subject to vesting in four equal annual installments from May 22, 2025, indicating a future commitment and potential increase in the executive's beneficial ownership over time, contingent on continued employment and performance.

Industry Context

The grant of restricted stock units (RSUs) to key executives is a standard and widely adopted practice across various industries, particularly in technology and healthcare, to attract, retain, and incentivize top talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The structure of this RSU grant, with a four-year annual vesting schedule, is a common and competitive practice for executive equity compensation in the medical device and biotechnology sectors, similar to compensation packages offered by companies like Abbott Laboratories (ABT), Medtronic (MDT), or Tandem Diabetes Care (TNDM) for their senior executives. Specific comparable projects or results are not applicable to a Form 4 filing.

Stakeholder Impact

• Shareholders: The grant aligns the executive's financial interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• The restricted stock units will vest in four equal annual installments from May 22, 2025, leading to the potential conversion of RSUs into common stock over time.

Key Dates

Keywords

Dexcom, DXCM, Form 4, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Jon Coleman, Equity Grant